Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349998 · ClinicalTrials.gov registry record · Phase 3
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
A Phase 3 study of Tinea Pedis and Tinea Cruris, sponsored by Tinea Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
- 20
- Study locations
NCT01349998 is a Phase 3 study of Tinea Pedis and Tinea Cruris that has completed, run by Tinea Pharmaceuticals. The registered enrollment target is 604 participants, above the 260-participant average among 9 other Tinea Pedis trials with a reported enrollment target (132% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01349998, a Phase 3 study of Tinea Pedis and Tinea Cruris, has completed, sponsored by Tinea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.
Conditions Studied
Interventions
- DRUG Product 33525
Study Locations (20)
Texas
- - Austin
- - College Station
- - Plano
- - San Antonio
Florida
- - Miami
- - Miramar
- - St. Petersburg
California
- - Fremont
- - Los Angeles
Pennsylvania
- - Hershey
- - Philadelphia
Georgia
- - Augusta
Indiana
- - Evansville
Michigan
- - Warren
Nebraska
- - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349998
The ClinicalTrials.gov registry entry for NCT01349998 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 260-participant average among 9 other Tinea Pedis trials with a reported enrollment target (132% higher). The listed sponsor is Tinea Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Tinea Pedis appearing as the primary indexed condition, and to 1 intervention - of which Product 33525 is the first listed.
NCT01349998 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01349998 about?
NCT01349998 is a clinical study titled "Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis". The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.
What is the current status of trial NCT01349998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2011-05. Estimated completion is 2012-09.
What conditions does trial NCT01349998 study?
This clinical trial studies the following conditions: Tinea Pedis, Tinea Cruris, Tinea Corporis.
What interventions are being tested in trial NCT01349998?
The interventions under investigation include: Product 33525 (DRUG).
Who is sponsoring clinical trial NCT01349998?
This trial is sponsored by Tinea Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01349998 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
COMPLETED · Phase 3
-
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
COMPLETED · Phase 3
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.